DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Cefuroxime |
DMSIMD8
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Cefuroxime. |
Acute bronchitis [CA42]
|
[15] |
Ivosidenib |
DM8S6T7
|
Moderate |
Increased metabolism of Nimodipine caused by Ivosidenib mediated induction of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[16] |
Arn-509 |
DMT81LZ
|
Major |
Increased metabolism of Nimodipine caused by Arn-509 mediated induction of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[17] |
Magnesium Sulfate |
DMVEK07
|
Moderate |
Additive neuromuscular blocking effects by the combination of Nimodipine and Magnesium Sulfate. |
Acute pain [MG31]
|
[18] |
Emapalumab |
DMZG5WL
|
Moderate |
Altered metabolism of Nimodipine due to Emapalumab alters the formation of CYP450 enzymes. |
Adaptive immunity immunodeficiency [4A01]
|
[19] |
Mitotane |
DMU1GX0
|
Major |
Increased metabolism of Nimodipine caused by Mitotane mediated induction of CYP450 enzyme. |
Adrenal cancer [2D11]
|
[17] |
Framycetin |
DMF8DNE
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Framycetin. |
Alcoholic liver disease [DB94]
|
[15] |
Cefamandole |
DMNEXZF
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Cefamandole. |
Anaerobic bacterial infection [1A00-1A09]
|
[15] |
Siltuximab |
DMGEATB
|
Moderate |
Altered metabolism of Nimodipine due to Siltuximab alters the formation of CYP450 enzymes. |
Anemia [3A00-3A9Z]
|
[19] |
Methylphenobarbital |
DMDSWAG
|
Moderate |
Increased metabolism of Nimodipine caused by Methylphenobarbital mediated induction of CYP450 enzyme. |
Anxiety disorder [6B00-6B0Z]
|
[20] |
Promazine |
DMZAL7W
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Promazine. |
Appearance/behaviour symptom [MB23]
|
[21] |
Voriconazole |
DMAOL2S
|
Major |
Decreased metabolism of Nimodipine caused by Voriconazole mediated inhibition of CYP450 enzyme. |
Aspergillosis [1F20]
|
[22] |
Posaconazole |
DMUL5EW
|
Major |
Decreased metabolism of Nimodipine caused by Posaconazole mediated inhibition of CYP450 enzyme. |
Aspergillosis [1F20]
|
[22] |
Zileuton |
DMVRIC2
|
Minor |
Decreased metabolism of Nimodipine caused by Zileuton mediated inhibition of CYP450 enzyme. |
Asthma [CA23]
|
[23] |
Cefotetan |
DM07TX3
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Cefotetan. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Kanamycin |
DM2DMPO
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Kanamycin. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Ceftazidime |
DM41GRA
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Ceftazidime. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Dalfopristin |
DM4LTKV
|
Moderate |
Decreased metabolism of Nimodipine caused by Dalfopristin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[24] |
Clarithromycin |
DM4M1SG
|
Major |
Decreased metabolism of Nimodipine caused by Clarithromycin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[22] |
Cefoperazone |
DM53PV8
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Cefoperazone. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Amikacin |
DM5PDRB
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Amikacin. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Cefprozil |
DM7DSYP
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Cefprozil. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Streptomycin |
DME1LQN
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Streptomycin. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Linezolid |
DMGFPU2
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Linezolid. |
Bacterial infection [1A00-1C4Z]
|
[25] |
Cefepime |
DMHVWIK
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Cefepime. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Cefpodoxime |
DMJUNY5
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Cefpodoxime. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Cefotaxime |
DMEB837
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Cefotaxime. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Cefazolin |
DMPDYFR
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Cefazolin. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Netilmicin |
DMRD1QK
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Netilmicin. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Tobramycin |
DMUI0CH
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Tobramycin. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Cefradine |
DMUNSWV
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Cefradine. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Cefixime |
DMY60I8
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Cefixime. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Cefoxitin |
DMY8NC4
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Cefoxitin. |
Bacterial infection [1A00-1C4Z]
|
[15] |
Telithromycin |
DMZ4P3A
|
Major |
Decreased metabolism of Nimodipine caused by Telithromycin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[22] |
Cariprazine |
DMJYDVK
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Cariprazine. |
Bipolar disorder [6A60]
|
[21] |
Erdafitinib |
DMI782S
|
Moderate |
Increased metabolism of Nimodipine caused by Erdafitinib mediated induction of CYP450 enzyme. |
Bladder cancer [2C94]
|
[26] |
Lapatinib |
DM3BH1Y
|
Moderate |
Decreased metabolism of Nimodipine caused by Lapatinib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[27] |
Tucatinib |
DMBESUA
|
Major |
Decreased metabolism of Nimodipine caused by Tucatinib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[22] |
Sotalol |
DML60TN
|
Moderate |
Increased risk of cardiac depression by the combination of Nimodipine and Sotalol. |
Cardiac arrhythmia [BC9Z]
|
[28] |
Secobarbital |
DM14RF5
|
Moderate |
Increased metabolism of Nimodipine caused by Secobarbital mediated induction of CYP450 enzyme. |
Chronic insomnia [7A00]
|
[20] |
Methohexital |
DM7YMIT
|
Moderate |
Increased metabolism of Nimodipine caused by Methohexital mediated induction of CYP450 enzyme. |
Corneal disease [9A76-9A78]
|
[20] |
Thiopental |
DMGP8AX
|
Moderate |
Increased metabolism of Nimodipine caused by Thiopental mediated induction of CYP450 enzyme. |
Corneal disease [9A76-9A78]
|
[20] |
Mifepristone |
DMGZQEF
|
Moderate |
Decreased metabolism of Nimodipine caused by Mifepristone mediated inhibition of CYP450 enzyme. |
Cushing syndrome [5A70]
|
[15] |
Pasireotide |
DMHM7JS
|
Moderate |
Increased risk of bradycardia by the combination of Nimodipine and Pasireotide. |
Cushing syndrome [5A70]
|
[29] |
Lumacaftor |
DMCLWDJ
|
Major |
Increased metabolism of Nimodipine caused by Lumacaftor mediated induction of CYP450 enzyme. |
Cystic fibrosis [CA25]
|
[17] |
Ivacaftor |
DMZC1HS
|
Moderate |
Decreased metabolism of Nimodipine caused by Ivacaftor mediated inhibition of CYP450 enzyme. |
Cystic fibrosis [CA25]
|
[30] |
MK-8228 |
DMOB58Q
|
Moderate |
Decreased metabolism of Nimodipine caused by MK-8228 mediated inhibition of CYP450 enzyme. |
Cytomegaloviral disease [1D82]
|
[31] |
Aprepitant |
DM053KT
|
Moderate |
Decreased metabolism of Nimodipine caused by Aprepitant mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[32] |
Fluoxetine |
DM3PD2C
|
Moderate |
Decreased metabolism of Nimodipine caused by Fluoxetine mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[29] |
Nefazodone |
DM4ZS8M
|
Major |
Decreased metabolism of Nimodipine caused by Nefazodone mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[22] |
Selegiline |
DM6034S
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Selegiline. |
Depression [6A70-6A7Z]
|
[25] |
Isocarboxazid |
DMAF1NB
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Isocarboxazid. |
Depression [6A70-6A7Z]
|
[25] |
OPC-34712 |
DMHG57U
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and OPC-34712. |
Depression [6A70-6A7Z]
|
[21] |
Phenelzine |
DMHIDUE
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Phenelzine. |
Depression [6A70-6A7Z]
|
[25] |
Primidone |
DM0WX6I
|
Major |
Increased metabolism of Nimodipine caused by Primidone mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[17] |
Oxcarbazepine |
DM5PU6O
|
Moderate |
Increased metabolism of Nimodipine caused by Oxcarbazepine mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[33] |
Mephenytoin |
DM5UGDK
|
Moderate |
Increased metabolism of Nimodipine caused by Mephenytoin mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[34] |
Cenobamate |
DM8KLU9
|
Moderate |
Increased metabolism of Nimodipine caused by Cenobamate mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[35] |
Stiripentol |
DMMSDOY
|
Moderate |
Decreased metabolism of Nimodipine caused by Stiripentol mediated inhibition of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[36] |
Fosphenytoin |
DMOX3LB
|
Major |
Increased metabolism of Nimodipine caused by Fosphenytoin mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[17] |
Ethotoin |
DMXWOCP
|
Moderate |
Increased metabolism of Nimodipine caused by Ethotoin mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[34] |
Phenobarbital |
DMXZOCG
|
Major |
Increased metabolism of Nimodipine caused by Phenobarbital mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[17] |
Carbamazepine |
DMZOLBI
|
Major |
Increased metabolism of Nimodipine caused by Carbamazepine mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[17] |
Nadolol |
DMW6GVL
|
Moderate |
Increased risk of cardiac depression by the combination of Nimodipine and Nadolol. |
Essential hypertension [BA00]
|
[28] |
Tazemetostat |
DMWP1BH
|
Moderate |
Increased metabolism of Nimodipine caused by Tazemetostat mediated induction of CYP450 enzyme. |
Follicular lymphoma [2A80]
|
[37] |
Itraconazole |
DMCR1MV
|
Major |
Decreased metabolism of Nimodipine caused by Itraconazole mediated inhibition of CYP450 enzyme. |
Fungal infection [1F29-1F2F]
|
[22] |
Miconazole |
DMPMYE8
|
Moderate |
Decreased metabolism of Nimodipine caused by Miconazole mediated inhibition of CYP450 enzyme. |
Fungal infection [1F29-1F2F]
|
[38] |
Ketoconazole |
DMPZI3Q
|
Major |
Decreased metabolism of Nimodipine caused by Ketoconazole mediated inhibition of CYP450 enzyme. |
Fungal infection [1F29-1F2F]
|
[22] |
Cimetidine |
DMH61ZB
|
Moderate |
Decreased metabolism of Nimodipine caused by Cimetidine mediated inhibition of CYP450 enzyme. |
Gastro-oesophageal reflux disease [DA22]
|
[39] |
Carteolol |
DMFMDOB
|
Moderate |
Increased risk of cardiac depression by the combination of Nimodipine and Carteolol. |
Glaucoma [9C61]
|
[28] |
Metipranolol |
DMJMVKI
|
Moderate |
Increased risk of cardiac depression by the combination of Nimodipine and Metipranolol. |
Glaucoma [9C61]
|
[40] |
Levobetaxolol |
DMSREPX
|
Moderate |
Increased risk of cardiac depression by the combination of Nimodipine and Levobetaxolol. |
Glaucoma [9C61]
|
[40] |
Levobunolol |
DMTNFCQ
|
Moderate |
Increased risk of cardiac depression by the combination of Nimodipine and Levobunolol. |
Glaucoma [9C61]
|
[40] |
Carvedilol |
DMHTEAO
|
Moderate |
Increased risk of cardiac depression by the combination of Nimodipine and Carvedilol. |
Heart failure [BD10-BD1Z]
|
[28] |
Furosemide |
DMMQ8ZG
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Furosemide. |
Heart failure [BD10-BD1Z]
|
[15] |
Boceprevir |
DMBSHMF
|
Major |
Decreased metabolism of Nimodipine caused by Boceprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[22] |
Simeprevir |
DMLUA9D
|
Moderate |
Decreased metabolism of Nimodipine caused by Simeprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[41] |
Telaprevir |
DMMRV29
|
Major |
Decreased metabolism of Nimodipine caused by Telaprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[22] |
Rifampin |
DMA8J1G
|
Major |
Increased metabolism of Nimodipine caused by Rifampin mediated induction of CYP450 enzyme. |
HIV-infected patients with tuberculosis [1B10-1B14]
|
[17] |
Rifapentine |
DMCHV4I
|
Major |
Increased metabolism of Nimodipine caused by Rifapentine mediated induction of CYP450 enzyme. |
HIV-infected patients with tuberculosis [1B10-1B14]
|
[42] |
Procarbazine |
DMIK367
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Procarbazine. |
Hodgkin lymphoma [2B30]
|
[25] |
Delavirdine |
DM3NF5G
|
Major |
Decreased metabolism of Nimodipine caused by Delavirdine mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[22] |
Fosamprenavir |
DM4W9B3
|
Moderate |
Decreased metabolism of Nimodipine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[43] |
Cobicistat |
DM6L4H2
|
Major |
Decreased metabolism of Nimodipine caused by Cobicistat mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[22] |
Efavirenz |
DMC0GSJ
|
Moderate |
Increased metabolism of Nimodipine caused by Efavirenz mediated induction of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[44] |
Saquinavir |
DMG814N
|
Major |
Decreased metabolism of Nimodipine caused by Saquinavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[22] |
Etravirine |
DMGV8QU
|
Moderate |
Increased metabolism of Nimodipine caused by Etravirine mediated induction of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[45] |
Amprenavir |
DMLMXE0
|
Moderate |
Decreased metabolism of Nimodipine caused by Amprenavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[43] |
Darunavir |
DMN3GCH
|
Moderate |
Decreased metabolism of Nimodipine caused by Darunavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[46] |
Atazanavir |
DMSYRBX
|
Major |
Decreased metabolism of Nimodipine caused by Atazanavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[22] |
Ritonavir |
DMU764S
|
Major |
Decreased metabolism of Nimodipine caused by Ritonavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[22] |
Acebutolol |
DM0TI4U
|
Moderate |
Increased risk of cardiac depression by the combination of Nimodipine and Acebutolol. |
Hypertension [BA00-BA04]
|
[28] |
Bisoprolol |
DM3UZ95
|
Moderate |
Increased risk of cardiac depression by the combination of Nimodipine and Bisoprolol. |
Hypertension [BA00-BA04]
|
[28] |
Penbutolol |
DM4ES8F
|
Moderate |
Increased risk of cardiac depression by the combination of Nimodipine and Penbutolol. |
Hypertension [BA00-BA04]
|
[28] |
Nebivolol |
DM7F1PA
|
Moderate |
Increased risk of cardiac depression by the combination of Nimodipine and Nebivolol. |
Hypertension [BA00-BA04]
|
[28] |
Labetalol |
DMK8U72
|
Moderate |
Increased risk of cardiac depression by the combination of Nimodipine and Labetalol. |
Hypertension [BA00-BA04]
|
[28] |
Conivaptan |
DM1V329
|
Major |
Decreased metabolism of Nimodipine caused by Conivaptan mediated inhibition of CYP450 enzyme. |
Hypo-osmolality/hyponatraemia [5C72]
|
[22] |
Givosiran |
DM5PFIJ
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Givosiran. |
Inborn porphyrin/heme metabolism error [5C58]
|
[15] |
Lesinurad |
DMUR64T
|
Moderate |
Increased metabolism of Nimodipine caused by Lesinurad mediated induction of CYP450 enzyme. |
Inborn purine/pyrimidine/nucleotide metabolism error [5C55]
|
[47] |
Berotralstat |
DMWA2DZ
|
Moderate |
Decreased metabolism of Nimodipine caused by Berotralstat mediated inhibition of CYP450 enzyme. |
Innate/adaptive immunodeficiency [4A00]
|
[48] |
Amobarbital |
DM0GQ8N
|
Moderate |
Increased metabolism of Nimodipine caused by Amobarbital mediated induction of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[20] |
Propiomazine |
DMKY8V1
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Propiomazine. |
Insomnia [7A00-7A0Z]
|
[21] |
ITI-007 |
DMUQ1DO
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and ITI-007. |
Insomnia [7A00-7A0Z]
|
[21] |
Selpercatinib |
DMZR15V
|
Moderate |
Decreased metabolism of Nimodipine caused by Selpercatinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[19] |
Idelalisib |
DM602WT
|
Major |
Decreased metabolism of Nimodipine caused by Idelalisib mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[22] |
IPI-145 |
DMWA24P
|
Moderate |
Decreased metabolism of Nimodipine caused by IPI-145 mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[49] |
Propranolol |
DM79NTF
|
Moderate |
Increased risk of cardiac depression by the combination of Nimodipine and Propranolol. |
Migraine [8A80]
|
[28] |
Exjade |
DMHPRWG
|
Moderate |
Decreased metabolism of Nimodipine caused by Exjade mediated inhibition of CYP450 enzyme. |
Mineral absorption/transport disorder [5C64]
|
[50] |
Thalidomide |
DM70BU5
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Nimodipine and Thalidomide. |
Multiple myeloma [2A83]
|
[15] |
Siponimod |
DM2R86O
|
Major |
Increased risk of atrioventricular block by the combination of Nimodipine and Siponimod. |
Multiple sclerosis [8A40]
|
[15] |
Fingolimod |
DM5JVAN
|
Moderate |
Increased risk of bradycardia by the combination of Nimodipine and Fingolimod. |
Multiple sclerosis [8A40]
|
[51] |
Ozanimod |
DMT6AM2
|
Moderate |
Increased risk of bradycardia by the combination of Nimodipine and Ozanimod. |
Multiple sclerosis [8A40]
|
[52] |
Rifabutin |
DM1YBHK
|
Major |
Increased metabolism of Nimodipine caused by Rifabutin mediated induction of CYP450 enzyme. |
Mycobacterium infection [1B10-1B21]
|
[42] |
Fedratinib |
DM4ZBK6
|
Moderate |
Decreased metabolism of Nimodipine caused by Fedratinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[19] |
Nilotinib |
DM7HXWT
|
Moderate |
Decreased metabolism of Nimodipine caused by Nilotinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[53] |
Imatinib |
DM7RJXL
|
Moderate |
Decreased metabolism of Nimodipine caused by Imatinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[54] |
Dasatinib |
DMJV2EK
|
Moderate |
Decreased metabolism of Nimodipine caused by Dasatinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[55] |
Modafinil |
DMYILBE
|
Moderate |
Increased metabolism of Nimodipine caused by Modafinil mediated induction of CYP450 enzyme. |
Narcolepsy [7A20]
|
[15] |
Entrectinib |
DMMPTLH
|
Moderate |
Decreased metabolism of Nimodipine caused by Entrectinib mediated inhibition of CYP450 enzyme. |
Non-small cell lung cancer [2C25]
|
[56] |
Rucaparib |
DM9PVX8
|
Moderate |
Decreased metabolism of Nimodipine caused by Rucaparib mediated inhibition of CYP450 enzyme. |
Ovarian cancer [2C73]
|
[57] |
Rasagiline |
DM3WKQ4
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Rasagiline. |
Parkinsonism [8A00]
|
[25] |
Lefamulin |
DME6G97
|
Moderate |
Decreased metabolism of Nimodipine caused by Lefamulin mediated inhibition of CYP450 enzyme. |
Pneumonia [CA40]
|
[58] |
Lonafarnib |
DMGM2Z6
|
Major |
Decreased metabolism of Nimodipine caused by Lonafarnib mediated inhibition of CYP450 enzyme. |
Premature ageing appearance [LD2B]
|
[22] |
Enzalutamide |
DMGL19D
|
Major |
Increased metabolism of Nimodipine caused by Enzalutamide mediated induction of CYP450 enzyme. |
Prostate cancer [2C82]
|
[17] |
Ustekinumab |
DMHTYK3
|
Moderate |
Altered metabolism of Nimodipine due to Ustekinumab alters the formation of CYP450 enzymes. |
Psoriasis [EA90]
|
[19] |
Levomepromazine |
DMIKFEL
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Levomepromazine. |
Psychotic disorder [6A20-6A25]
|
[21] |
Fluphenazine |
DMIT8LX
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Fluphenazine. |
Psychotic disorder [6A20-6A25]
|
[21] |
Triflupromazine |
DMKFQJP
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Triflupromazine. |
Psychotic disorder [6A20-6A25]
|
[21] |
Temsirolimus |
DMS104F
|
Moderate |
Increased plasma concentrations of Nimodipine and Temsirolimus due to competitive inhibition of the same metabolic pathway. |
Renal cell carcinoma [2C90]
|
[59] |
Tocilizumab |
DM7J6OR
|
Moderate |
Altered metabolism of Nimodipine due to Tocilizumab alters the formation of CYP450 enzymes. |
Rheumatoid arthritis [FA20]
|
[19] |
Canakinumab |
DM8HLO5
|
Moderate |
Altered metabolism of Nimodipine due to Canakinumab alters the formation of CYP450 enzymes. |
Rheumatoid arthritis [FA20]
|
[19] |
Rilonacept |
DMGLUQS
|
Moderate |
Altered metabolism of Nimodipine due to Rilonacept alters the formation of CYP450 enzymes. |
Rheumatoid arthritis [FA20]
|
[19] |
Golimumab |
DMHZV7X
|
Moderate |
Altered metabolism of Nimodipine due to Golimumab alters the formation of CYP450 enzymes. |
Rheumatoid arthritis [FA20]
|
[19] |
Sarilumab |
DMOGNXY
|
Moderate |
Altered metabolism of Nimodipine due to Sarilumab alters the formation of CYP450 enzymes. |
Rheumatoid arthritis [FA20]
|
[19] |
Quetiapine |
DM1N62C
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Quetiapine. |
Schizophrenia [6A20]
|
[21] |
Mesoridazine |
DM2ZGAN
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Mesoridazine. |
Schizophrenia [6A20]
|
[21] |
Thioridazine |
DM35M8J
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Thioridazine. |
Schizophrenia [6A20]
|
[21] |
Aripiprazole |
DM3NUMH
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Aripiprazole. |
Schizophrenia [6A20]
|
[21] |
Iloperidone |
DM6AUFY
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Iloperidone. |
Schizophrenia [6A20]
|
[21] |
Paliperidone |
DM7NPJS
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Paliperidone. |
Schizophrenia [6A20]
|
[21] |
Loxapine |
DM8AI9U
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Loxapine. |
Schizophrenia [6A20]
|
[21] |
Haloperidol |
DM96SE0
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Haloperidol. |
Schizophrenia [6A20]
|
[21] |
Perphenazine |
DMA4MRX
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Perphenazine. |
Schizophrenia [6A20]
|
[21] |
Molindone |
DMAH70G
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Molindone. |
Schizophrenia [6A20]
|
[21] |
Chlorpromazine |
DMBGZI3
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Chlorpromazine. |
Schizophrenia [6A20]
|
[21] |
Thiothixene |
DMDINC4
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Thiothixene. |
Schizophrenia [6A20]
|
[21] |
Risperidone |
DMN6DXL
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Risperidone. |
Schizophrenia [6A20]
|
[21] |
Amisulpride |
DMSJVAM
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Amisulpride. |
Schizophrenia [6A20]
|
[21] |
Asenapine |
DMSQZE2
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Asenapine. |
Schizophrenia [6A20]
|
[21] |
Voxelotor |
DMCS6M5
|
Moderate |
Decreased metabolism of Nimodipine caused by Voxelotor mediated inhibition of CYP450 enzyme. |
Sickle-cell disorder [3A51]
|
[60] |
Telotristat ethyl |
DMDIYFZ
|
Moderate |
Increased metabolism of Nimodipine caused by Telotristat ethyl mediated induction of CYP450 enzyme. |
Small intestine developmental anomaly [DA90]
|
[19] |
Larotrectinib |
DM26CQR
|
Moderate |
Decreased metabolism of Nimodipine caused by Larotrectinib mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[15] |
Ifosfamide |
DMCT3I8
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Ifosfamide. |
Solid tumour/cancer [2A00-2F9Z]
|
[15] |
Armodafinil |
DMGB035
|
Moderate |
Increased metabolism of Nimodipine caused by Armodafinil mediated induction of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[15] |
LEE011 |
DMMX75K
|
Moderate |
Decreased metabolism of Nimodipine caused by LEE011 mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[61] |
Pitolisant |
DM8RFNJ
|
Moderate |
Increased metabolism of Nimodipine caused by Pitolisant mediated induction of CYP450 enzyme. |
Somnolence [MG42]
|
[19] |
Fostamatinib |
DM6AUHV
|
Moderate |
Decreased clearance of Nimodipine due to the transporter inhibition by Fostamatinib. |
Thrombocytopenia [3B64]
|
[62] |
Sirolimus |
DMGW1ID
|
Moderate |
Increased plasma concentrations of Nimodipine and Sirolimus due to competitive inhibition of the same metabolic pathway. |
Transplant rejection [NE84]
|
[59] |
Plazomicin |
DMKMBES
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Plazomicin. |
Urinary tract infection [GC08]
|
[15] |
Nalidixic acid |
DMRM0JV
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nimodipine and Nalidixic acid. |
Urinary tract infection [GC08]
|
[15] |
Methdilazine |
DMAUHQX
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Methdilazine. |
Vasomotor/allergic rhinitis [CA08]
|
[21] |
Trimeprazine |
DMEMV9D
|
Moderate |
Additive hypotensive effects by the combination of Nimodipine and Trimeprazine. |
Vasomotor/allergic rhinitis [CA08]
|
[63] |
----------- |
|
|
|
|
|